Ajanta Pharma Ltd. reported a strong Q1FY27 performance, with consolidated net profit rising nearly 31% on the back of robust growth in its US generics and domestic businesses, while the board approved an interim dividend of Rs 32 per share.
The drugmaker posted a 30.9% year-on-year increase in consolidated net profit to Rs 334 crore for the quarter ended June, compared with Rs 255 crore a year earlier. Revenue from operations grew 24.8% to Rs 1,626 crore from Rs 1,303 crore in the corresponding quarter last year.
Ajanta Pharma Q1 Results - Cons, YoY
- Net profit up 30.9% at Rs 334 crore vs Rs 255 crore YoY
- Revenue up 24.8% at Rs 1,626 crore vs Rs 1,303 crore YoY
- EBITDA up 20.5% at Rs 423 crore vs Rs 351 crore YoY
- EBITDA margin at 26% vs 26.9% YoY
Segment Performance
- US Generics business up 57% at Rs 487 crore YoY
- India business up 24% at Rs 509 crore YoY
- Asia business down 16% at Rs 255 crore YoY
- Africa business up 30% at Rs 295 crore YoY
Operating performance remained healthy, with EBITDA rising 20.5% to Rs 423 crore. However, the EBITDA margin narrowed to 26% from 26.9% a year ago, indicating that operating costs grew at a faster pace than revenue.
Separately, Ajanta Pharma's board approved an interim dividend of Rs 32 per equity share, taking the total dividend payout for the quarter to Rs 400 crore.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
